1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Pragma Pharmaceuticals Acquires Shionogi - Keflex

M&A Deal Summary

Pragma Pharmaceuticals Acquires Shionogi - Keflex

On April 6, 2016, Pragma Pharmaceuticals acquired life science company Shionogi - Keflex from Shionogi

Acquisition Highlights
  • This is Pragma Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Pragma Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2016-04-06
Target Shionogi - Keflex
Sector Life Science
Buyer(s) Pragma Pharmaceuticals
Sellers(s) Shionogi
Deal Type Divestiture

Target

Shionogi - Keflex

United States
Shionogi - Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Pragma Pharmaceuticals

Locust Valley, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Pragma Pharmaceuticals LLC is a pharmaceutical firm.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1

Seller(S) 1

SELLER

Shionogi

Florham Park, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Shionogi Inc. is the U.S.-based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company. Shionogi Inc., develops and commercializes pharmaceutical products that address unmet medical needs. Together with our Japanese corporate parent, Shionogi has been providing innovative medicines essential to people's health for over 130 years. This partnership sets the stage for further expansion of our global business with expectations for Shionogi Inc. to become an even more significant contributor to our world-wide results.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Divestiture M&A Deals 1 of 2
Country: United States M&A 1 of 2
Year: 2016 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-18 Victory Pharma

San Diego, California, United States

Victory Pharma, Inc., a specialty pharmaceutical company, engages in acquiring, developing and marketing prescription pharmaceutical products for the treatment of pain and related conditions. The company also develops products that treat pain and minimize side effects associated with widely-used pain therapeutics. Its products include NAPRELAN tablets for the treatment of rheumatoid arthritis, osteoarthritis, XODO for the relief of moderate to moderately sever pain, and Dolgic Plus tablets for tension headache.

Buy $127M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-10 Shionogi - Osphena

Florham Park, New Jersey, United States

Shionogi, Inc. - Osphena is an oral, non-hormonal prescription medication indicated for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.

Sell -
Mergr

Solution for

Product

Company

Legal